


Wegovy® (semaglutide) is an FDA-approved GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related medical condition, when used alongside diet and exercise.
Wegovy (semaglutide) belongs to a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1s). These medications mimic a naturally occurring hormone involved in regulating appetite and blood sugar levels.
By acting on appetite and metabolic pathways, Wegovy supports weight reduction efforts when combined with dietary changes and increased physical activity.
Wegovy is available in two formulations containing the same active ingredient, semaglutide.
Side effects: Potential side effects are similar between formulations and may be monitored and managed by your physician.
GLP-1 medications are indicated for chronic weight management in adults with obesity or overweight (with weight-related medical conditions) when used alongside diet and exercise.
These medications may have serious side effects, including a possible risk of thyroid tumors. Wegovy should not be used if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
A full medical evaluation is required to determine if Wegovy is appropriate for you. Discuss all risks and benefits with your physician.
*Based on manufacturer clinical trials studying the highest doses of oral and injectable semaglutide in adults without diabetes who had obesity or overweight with at least one weight-related condition, when combined with diet and exercise changes (compared to approximately 2% with diet and exercise alone).
Wegovy uses a GLP-1 hormone to help reduce appetite, control cravings, and make you feel full longer.